Atuzaginstat for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Jan 2019: Trial registered, NCT03823404
  2. 28 Mar 2019: Trial started, NCT03823404

The trials

NCT03823404: GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

State
Completed
Phase
Phase 2 and Phase 3
People
643 taking part
Started
28 Mar 2019
Primary completion
1 Jan 2022
Arms
COR388 80 mg twice daily (BID), COR388 40 mg BID
Results
Posted on the registry
  1. 30 Jan 2019: Trial registered
  2. 28 Mar 2019: Trial started
  3. 1 Jan 2022: Trial completed
  4. 23 Feb 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as COR388 capsule.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.